MHRA inspection process
At the recent MHRA GDP Symposium held in February the inspectorate announced a change to the MHRA inspection process.
At the recent MHRA GDP Symposium held in February the inspectorate announced a change to the MHRA inspection process.
Anyone who has recently reviewed the Medicines and Healthcare products Regulatory Agency (MHRA) CMS may have noticed the notification at the bottom of the search page regarding GMP and GDP Certificates, stating the following
MHRA Guidance Note 6 – Notes for applicants and holders of a Wholesale Dealer’s Licence (WDA(H)) or Broker Registration was updated in November 2022 with some significant changes regarding Brexit.
On the 16th of November 2022 the Medicines and Healthcare products Regulatory Agency (MHRA) released a blog with guidance on the process for approving Manufacturing Authorisations/ API Registrations in relation to unlicensed Cannabis-Based Products for Medicinal (CBPM) use.
On the 7th of October The Medicines and Healthcare products Regulatory Agency (MHRA) released a response to contaminated paediatric medicines identified by the WHO region of Africa.
The Early Access to Medicines Scheme (EAMS) launched in 2014 and allows patients with unmet clinical needs to gain early access to unlicensed medicines and medicines to be used outside of their licence.